For research use only
| Cat No. | ABC-TC0056 |
| Product Type | Human Breast Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Breast |
| Disease | Adenocarinoma |
| Product Code | AU565; AU 565 |
AU-565 Breast Cancer Cells are HER2-positive and support drug response testing, gene amplification modeling, and receptor-targeted strategies.
AU-565 cell line is a human epithelial breast carcinoma cell line originally established from the pleural effusion of a 43-year-old Caucasian female with metastatic breast adenocarcinoma. AU-565 cells grow as loosely adherent clusters and exhibit epithelial cobblestone-like morphology in vitro. The line is estrogen receptor (ER) and progesterone receptor (PR) negative, but displays strong HER2 overexpressione. Cytogenetic analyses reveal hypertriploidy and complex structural chromosomal abnormalities typical of advanced breast tumors. AU-565 is tumorigenic in immunocompromised mice and is widely used in HER2-targeted therapy development, signal transduction studies, and drug resistance research. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | AU565; AU 565 |
| Species | Human |
| Cat.No | ABC-TC0056 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Breast |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
AU-565 is extensively utilized as a HER2-positive breast cancer model for preclinical evaluation of anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors. Its defined molecular profile, including HER2 amplification and ER/PR negativity, supports studies in targeted drug response, downstream signaling cascades, and trastuzumab resistance mechanisms. AU-565 also aids in biomarker validation, antibody-drug conjugate testing, and assessment of combination therapies involving HER2-targeted agents. The line’s tumorigenicity and stable phenotype in xenograft models make it ideal for translational breast cancer research. AU-565 is frequently used in parallel with SK-BR-3 for comparative analyses and high-throughput drug screening in HER2-dominant breast tumors.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
